Stryker (NYSE:SYK) PT Raised to $381.00

Stryker (NYSE:SYK) had its price objective boosted by equities research analysts at Wells Fargo & Company from $364.00 to $381.00 in a report issued on Wednesday, Benzinga reports. The brokerage presently has an “overweight” rating on the medical technology company’s stock. Wells Fargo & Company‘s target price suggests a potential upside of 16.61% from the company’s current price.

SYK has been the topic of several other reports. UBS Group boosted their price objective on shares of Stryker from $339.00 to $351.00 and gave the company a “neutral” rating in a report on Wednesday. Citigroup boosted their price target on shares of Stryker from $362.00 to $406.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Stifel Nicolaus boosted their price target on shares of Stryker from $350.00 to $375.00 and gave the stock a “buy” rating in a research note on Wednesday. TD Cowen boosted their price target on shares of Stryker from $365.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, April 11th. Finally, Evercore ISI boosted their price target on shares of Stryker from $340.00 to $370.00 and gave the stock an “outperform” rating in a research note on Thursday, April 4th. Four analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $365.94.

Stryker Stock Down 0.4 %

Shares of SYK opened at $326.73 on Wednesday. The firm has a market cap of $124.31 billion, a P/E ratio of 37.30, a price-to-earnings-growth ratio of 2.63 and a beta of 0.91. Stryker has a 12-month low of $249.98 and a 12-month high of $361.41. The company’s 50-day moving average price is $347.52 and its 200 day moving average price is $316.85. The company has a current ratio of 1.71, a quick ratio of 0.97 and a debt-to-equity ratio of 0.56.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.36 by $0.14. The firm had revenue of $5.24 billion for the quarter, compared to analyst estimates of $5.10 billion. Stryker had a net margin of 16.03% and a return on equity of 23.05%. Stryker’s revenue was up 9.7% on a year-over-year basis. During the same period in the previous year, the firm earned $2.14 EPS. On average, sell-side analysts forecast that Stryker will post 11.93 earnings per share for the current year.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 201,146 shares of the stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $342.90, for a total value of $68,972,963.40. Following the transaction, the director now directly owns 3,755,128 shares in the company, valued at $1,287,633,391.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Stryker news, Director Ronda E. Stryker sold 201,146 shares of the stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $342.90, for a total value of $68,972,963.40. Following the transaction, the director now directly owns 3,755,128 shares in the company, valued at $1,287,633,391.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO William E. Berry, Jr. sold 7,690 shares of the stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $358.48, for a total value of $2,756,711.20. Following the completion of the sale, the chief accounting officer now directly owns 3,675 shares of the company’s stock, valued at $1,317,414. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Stryker

Several large investors have recently modified their holdings of the company. Aspen Investment Management Inc boosted its holdings in shares of Stryker by 0.7% in the first quarter. Aspen Investment Management Inc now owns 4,368 shares of the medical technology company’s stock valued at $1,563,000 after acquiring an additional 31 shares during the period. Harbor Investment Advisory LLC lifted its holdings in shares of Stryker by 0.4% during the first quarter. Harbor Investment Advisory LLC now owns 6,982 shares of the medical technology company’s stock worth $2,499,000 after purchasing an additional 31 shares during the period. Bremer Bank National Association lifted its holdings in shares of Stryker by 4.0% during the fourth quarter. Bremer Bank National Association now owns 888 shares of the medical technology company’s stock worth $266,000 after purchasing an additional 34 shares during the period. Simon Quick Advisors LLC lifted its holdings in shares of Stryker by 3.0% during the fourth quarter. Simon Quick Advisors LLC now owns 1,158 shares of the medical technology company’s stock worth $347,000 after purchasing an additional 34 shares during the period. Finally, Consolidated Portfolio Review Corp lifted its holdings in shares of Stryker by 3.6% during the fourth quarter. Consolidated Portfolio Review Corp now owns 983 shares of the medical technology company’s stock worth $294,000 after purchasing an additional 34 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.